RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

Assess your risk of contracting H1N1 swine flu with our easy-to-use Swine Flu Risk Calculator. Identify risk factors, ...

Moderna this week announced positive data from a phase 3 trial of its messenger RNA vaccine against seasonal influenza, which ...

The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.

Moderna's mRNA flu vaccine showed 26.6% better efficacy than a standard flu shot in adults 50 and older during a global Phase ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

MRNA's mRNA-1010 flu vaccine outperforms GSK's shot by 26.6% in a large phase III trial of adults 50 and older.

Moderna has reported positive phase 3 results for its seasonal flu vaccine, mRNA-1010, which outperformed a standard-dose ...

The Eastern Regional Health Directorate is closely monitoring a suspected outbreak of H1N1 influenza at Anum Presbyterian and ...

Nine students of Anum Senior High School in the Asuogyaman District of the Eastern Region have tested positive for the H1N1 ...

Moderna's experimental flu vaccine demonstrated superior efficacy compared to standard flu vaccines in late-stage trials.